Get started
Author

Th. Behr

Observed names: Behr, T. M., Th Behr, Th. M. Behr
OpenAlex ID: A5111473770
Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study
2006 · P H Kann, E Balakina, et al. · Endocrine Related Cancer · 106
PDF
Sentinel node detection in N0 cancer of the pharynx and larynx
2002 · J A Werner, A-A Dünne, et al. · British Journal of Cancer · 91
PDF
Value of sentinel lymphonodectomy in head and neck cancer patients without evidence of lymphogenic metastatic disease
2001 · Anja-A. Dünne, Christoph Külkens, et al. · Auris Nasus Larynx · 50
Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy
2002 · M. Gotthardt, W. Becker, et al. · Nuklearmedizin - NuclearMedicine · 41
High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 Rituximab
2001 · W. Becker, Th. Behr · Annals of Hematology · 3
Ga-67-citrate Versus Tc-99m-labelled Ll2-fab'-fragments (anti-cd22) in the Staging of B-cell Non-hodgkinʼs Lymphoma (nhl)
1994 · W. Becker, Th. Behr, et al. · Journal of Immunotherapy · 3
Die Rolle der Endosonographie in der Detektion und Klassifizierung des Phäochromozytoms
2005 · S. Meyer, B. Kann, et al. · Nieren- und Hochdruckkrankheiten · 1
Neuroendocrine Gastro-Entero-Pancreatic (GEP) Tumors
2004 · R. Arnold, R. GöKe, et al. · Springer eBooks · 1
Nuclear Medicine diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract, including carcinoids
2003 · Th. Behr, Martin Gotthardt, et al. · 1
Metabolites of In-111-DTPA-DGlu(1)-mini-gastrins in different organs.
2003 · Behe, M., Gotthardt, M., et al. · GRO
Comparison of HYNIC and N-α-HIS substituted minigastrin derivatives to marking with technetium-99m
2002 · E. Guggenberg von, Martin Béhé, et al. · Nuklearmedizin - NuclearMedicine
Cholecystokinin(CCK)-B/gastrin-receptor binding peptides for diagnosis and therapy of metastatic medullary thyroid cancer (MTC)
2002 · Th. Behr, Martin Gotthardt, et al. · World Journal of Nuclear Medicine
Factors influencing the therapeutic outcome of I-131 therapy of differentiated thyroid cancer (DTC): Do we really need stimulated TSH levels?
2002 · Th. Behr, Meike L. Schipper, et al. · GRO
High-dose myeloablative versus conventional low-dose radiommunotherapy (RIT) of mantle cell lymphoma (MCL) with the chimeric anti-CD20 antibody C2B8.
2002 · Behr, T. M., Gotthardt, M., et al. · GRO
Does external scintigraphy allow for predictions with respect to the toxicity and therapeutic efficacy of Herceptin (R) therapy of HER2/neu expressing breast cancer?
2002 · Behr, T. M., Wormann, B., et al. · GRO
Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy - A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Gottingen/Marburg Experience
2002 · Behr, T. M., Gotthardt, M., et al. · GRO
Internalisation of In-111-DTPA-DGlu(1)-minigastrin.
2002 · Behe, M., Becker, W., et al. · GRO
Kidney protection agents during radiopeptide therapy in mice.
2002 · Behe, M., Kluge, G., et al. · GRO
Radiopeptide therapy with cholecysto-kinin (CCK)-B gastrin receptor ligands: Toxicity and therapeutic efficacy of auger E- versus alpha or beta emitters.
2001 · Behr, T. M., Behe, M. P., et al. · GRO
Factors influencing the dosimetry and the therapeutic outcome of radioiodine (I-131) therapy of differentiated thyroid cancer
2001 · Behr, T. M., Behe, M., et al. · GRO
High-dose radioimmunotherapy (RIT) of mantle cell lymphoma (MCL) with the I-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support.
2001 · Behr, T. M., Griesinger, Frank, et al. · GRO
Does immunoscintigraphy allow for prognostic predictions with respect to the toxicity and therapeutic efficacy of herceptin immunotherapy of metastatic breast cancer?
2001 · Behr, T. M., Behe, M., et al. · GRO
Does immunoscintigraphy allow for prognostic predictions with respect to the toxicity and therapeutic efficacy of Herceptin (R) immunotherapy of metastatic breast cancer?
2001 · Behr, T. M., Behe, M. P., et al. · GRO
Cholecystokinin (CCK)-B/gastrin-receptor binding peptides for diagnosis and therapy of metastatic medullary thyroid cancer.
2001 · Behr, T. M., Behe, M., et al. · GRO
Factors influencing the dosimetry and the therapeutic outcome of I-131 therapy of differentiated thyroid cancer (DTC).
2001 · Behr, T. M., Behe, M. P., et al. · GRO
Works count: 44
Citation count: 297
H-index: 4
I10-index: 4
Year
Topic
Type